---
title: "TKI discontinuation"
slug: "tki-discontinuation"
date: "2023-05-25"
enableToc: false
tags:
- building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[treatment of chronic myelogenous leukemia (CML)]]

# TKI discontinuation

consider if complete molecular response (>4.5 log reduction inÂ BCR-ABL1Â transcript) for >2 y. Up to 50% of Pts remain off TKI at 2 y (ie, no molec. recurrence). Success proportional to duration of CMR and risk score at presentation.
